Friday, 14 Jun 2019

You are here

My ACR Takeaways

With ACR 2017 winding down and the sheer volume of information seemingly overwhelming, I wanted to take the time to write an article regarding a few tips I learned that I will use in clinical practice. 

1. With regards to the flu vaccine, holding MTX for two weeks after the flu vaccine will increase immunogenicity without worsening disease. 
2. CAPS is a complementopathy and Eculizumab (anti-C5a) is approved for treatment, though is expensive
3. 1% of GPA patients can present with pituitary involvement and respond to Cytoxan or Rituxan
4. HCQ should be a mainstay in APS therapy – can reduce size of thrombus and number of potential events. 
5. MMF at 3 grams is not superior to 2 grams in rheum-related ILD
6. RA and SpA remission patients fare better with continued therapy than with withdrawal 
7. A healthy mom is the best thing for a healthy baby in terms of safety of continuing DMARDs and bDMARDs during pregnancy and lactation. 
8. Options for MACRA and MIPs data submission supported by ACR include the RISE registry and RCR

While this list barely scratches the surface, it’s a helpful start to digesting data from ACR to use for our day to day practice. I’m looking forward to hearing more about upcoming guidelines, updated diagnostic criteria, telemedicine, and US advances in both the education and diagnostic realms. 

Until Chicago!

 


Rheumatologists' Comments

Dear Rachel Tate, it´s a fantastic compilation of the ACR on what we should start (or keep) doing. Congratulations, Carlos Antonio Moura

More Like This

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA

EULAR 2019 Report – Day 2

It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid 

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed.